Clin2
NCT07511010Likely a fitNot yet recruiting

How food affects a new diabetes pill and its multiple doses

T2DM (Type 2 Diabetes Mellitus)

Part of Hormones & metabolism clinical trials.

This trial tests how a new medication (chiglitazar combined with metformin extended-release) works in the body when taken with food and after multiple doses. Healthy volunteers are needed to help understand the drug's safety and how it is processed.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
28 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You are between 18 and 45 years old
  • Your body mass index (BMI) is between 19 and 26
  • You weigh at least 50 kg (if male) or 45 kg (if female)
  • You have not taken any prescription or over-the-counter medications, vitamins, or herbal supplements in the last month
  • You do not smoke more than 5 cigarettes a day and can stop smoking during the study
  • You do not drink more than 14 units of alcohol per week and can avoid alcohol during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07519265Not yet recruiting
Testing a new diabetes and heart health medication

This study compares two versions of a combination medication (chiglitazar and metformin) to ensure they work the same way in the body. Researchers are recruiting healthy volunteers to help determine if the new formulation is equivalent to the standard version.

NCT07412015Not yet recruiting
Testing a new diabetes combination pill in healthy people

This study tests how well a new combination diabetes medication (chiglitazar/metformin) works in the body compared to taking the two drugs separately. It is for healthy volunteers and helps ensure the new pill is safe and effective.

NCT07580638Not yet recruiting
Adding Chiglitazar to SGLT-2 Inhibitors for Type 2 Diabetes

This trial tests whether adding a new diabetes medication called chiglitazar to your current SGLT-2 inhibitor can help lower your blood sugar better. You may qualify if your blood sugar is still too high despite taking an SGLT-2 inhibitor, and this study could help find better ways to control your diabetes.

NCT07244003Recruiting· Phase 4
Testing metformin with two newer diabetes drugs

This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.

Tianjin, Tianjin Municipality
NCT07441187Not yet recruiting
A study of diabetes medicines for Chinese adults with type 2 diabetes

This trial tests a combination of three diabetes medicines (henagliflozin, retagliptin, and extended-release metformin) to see if they are safe and effective for Chinese adults with type 2 diabetes. You may join if you are newly diagnosed or have been taking one oral diabetes pill but need better blood sugar control.

NCT07303803Recruiting· Phase 2
Testing Chiglitazar for fatty liver with diabetes

This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.

Beijing, Beijing Municipality

Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.